Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ELOS
CUSIPN/A
Phone+972-7-32442200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.68
Quick Ratio1.84
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1.09%
Return on Equity-1.74%
Return on Assets-1.30%
Miscellaneous
Employees817
Outstanding Shares35,230,000
Market Cap$387.56 million
Syneron Medical (NASDAQ:ELOS) Frequently Asked Questions
What is Syneron Medical's stock symbol?
Syneron Medical trades on the NASDAQ under the ticker symbol "ELOS."
How were Syneron Medical's earnings last quarter?
Syneron Medical Ltd. (NASDAQ:ELOS) released its quarterly earnings data on Thursday, August, 4th. The medical equipment provider reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. The medical equipment provider had revenue of $75 million for the quarter, compared to the consensus estimate of $75.72 million. Syneron Medical had a negative return on equity of 1.74% and a negative net margin of 1.09%. Syneron Medical's quarterly revenue was up 2.0% on a year-over-year basis. During the same period last year, the business posted $0.07 EPS. View Syneron Medical's Earnings History.
Who are Syneron Medical's key executives?
Syneron Medical's management team includes the folowing people:
- Shimon Eckhouse Ph.D., Chairman of the Board
- Amit Meridor, Chief Executive Officer
- , Bio & Compensation -
- Hugo Goldman, Chief Financial Officer
- , Bio & Compensation -
- Erik Dowell, Vice President-North America
- William Griffing, Chief Executive Officer - Syneron Candela North America
- Shlomo Alkalay, Chief Operating Officer
- Lisa A. Soderquist, Chief Human Resource Officer
- , Bio & Compensation -
- Robert Ruck, Executive Vice President, Asia Pacific
- Robert Fielitz, Vice President and Managing Director of Europe, Middle East and Africa
- Sarit Soccary Ben-Yochanan, Vice President - Business Development & Strategy
How do I buy shares of Syneron Medical?
Shares of ELOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneron Medical's stock price today?
One share of ELOS stock can currently be purchased for approximately $11.00.
How big of a company is Syneron Medical?
Syneron Medical has a market capitalization of $387.56 million. Syneron Medical employs 817 workers across the globe.
What is Syneron Medical's official website?
How can I contact Syneron Medical?
Syneron Medical's mailing address is Tavor Building 4 P.O. Box 550, YOKNEAM, 2069200, Israel. The medical equipment provider can be reached via phone at +972-7-32442200.
MarketBeat Community Rating for Syneron Medical (NASDAQ ELOS)
MarketBeat's community ratings are surveys of what our community members think about Syneron Medical and other stocks. Vote "Outperform" if you believe ELOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
